China remains one of the world’s most important medical technology markets, but understanding the market in 2026 requires more than looking at its size.

For global MedTech companies, the more important questions are increasingly specific:

How quickly can an innovative device obtain regulatory approval? How will a Chinese public hospital purchase it? Can the hospital charge for the clinical service enabled by the device? Is the product exposed to centralized procurement or price pressure? And how strong are Chinese competitors becoming in the same category?

These questions are now interconnected.

China’s MedTech market is entering a period in which regulatory approval, hospital procurement, medical service pricing, reimbursement, localization and product economics increasingly determine commercialization together.

Here are seven structural changes global MedTech executives should understand in 2026.

China MedTech Market 2026: At a Glance

China Continues to Accelerate the Approval of Innovative Medical Devices

China’s regulatory system continues to provide dedicated pathways for innovative and clinically valuable medical technologies.

According to the National Medical Products Administration (NMPA), 76 innovative medical devices were approved in China in 2025, an increase of 17% year over year. Another 25 devices entered the priority approval pathway, up 212.5% from the previous year. Approved products covered fields including artificial intelligence, radiation oncology and advanced biomaterials.

This matters because China should no longer be viewed simply as a market where overseas technologies arrive after they have matured elsewhere.

Chinese regulators are increasingly dealing with technologies that are being developed, clinically validated and commercialized inside China at the same time as — and occasionally ahead of — other major markets.

Surgical robotics provides a useful example. Chinese companies are developing multi-port, single-port, orthopedic, neurosurgical, dental, endoluminal and interventional robotic platforms, creating a much more diversified regulatory pipeline than existed several years ago.

For international companies, the implication is straightforward:

China regulatory strategy increasingly needs to be considered as part of global product strategy rather than as a late-stage market-entry exercise.

Domestic MedTech Companies Are Moving Further Into High-End Categories

“Domestic substitution” is often used to describe China’s medical device industry, but the phrase increasingly understates what is happening.

Chinese manufacturers are no longer competing only in relatively standardized products.

They are expanding into technically demanding categories including surgical robotics, advanced imaging, electrophysiology, structural heart devices, neurointervention, ophthalmology and digital surgery.

MedChina’s own surgical robotics data illustrates the shift.

MedRobot identified at least 366 surgical robot systems sold by Chinese manufacturers in the first half of 2026, covering endoscopic surgery, orthopedics, neurosurgery, dentistry, natural-orifice surgery and percutaneous intervention.

In mainland China’s publicly disclosed endoscopic surgical robot procurement market, domestic systems accounted for approximately 63% of awarded units in H1 2026, compared with 38% during the same period in 2025.

This does not mean multinational manufacturers are disappearing from China.

It means the basis of competition is changing.

Global companies increasingly compete with Chinese manufacturers not only on price, but also on clinical evidence, product iteration speed, local service capability, physician training, manufacturing localization and integration with Chinese hospital workflows.

Public-Hospital Equipment Procurement Is Becoming More Disciplined

China’s public hospitals remain the most important institutional customers for many medical technologies.

But the purchasing environment has become increasingly sensitive to budgets, utilization and procurement compliance.

A major policy development arrived in July 2026.

China’s National Health Commission, together with the National Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration, issued requirements stating that public medical and health institutions purchasing medical equipment included in departmental centralized procurement catalogues with budget-managed funds must conduct such purchases through departmental centralized procurement.

The detailed impact will depend on equipment category and implementation.

But the broader direction is clear:

Winning NMPA approval does not automatically translate into hospital purchases.

Manufacturers increasingly need to answer several additional questions:

• Does the hospital have the budget?

• How will the device enter the procurement process?

• What utilization level can the hospital realistically achieve?

• Can the device reduce other costs or improve clinical capacity?

• How does its total cost compare with competing systems?

For high-value capital equipment, these questions are becoming central to commercial strategy.

Medical Service Pricing Is Becoming Part of MedTech Commercialization

One of the most important developments in China is occurring outside traditional medical-device regulation.

China is progressively restructuring its medical service pricing system.

By the first half of 2026, the National Healthcare Security Administration (NHSA) reported that it had issued 39 batches of medical service pricing guidelines, incorporating more than 170 new technologies and products, including surgical robots and brain-computer interfaces, into medical service pricing frameworks.

Surgical robotics illustrates how important this can be.

In January 2026, the NHSA established standardized pricing categories for robot-assisted procedures based on the robot’s level of participation in surgery, including navigation, assisted execution and precision execution. The framework is designed to allow different types of surgical robots to fit within a common service-pricing structure rather than creating separate charging items for every device or surgical approach.

This represents a fundamental commercialization issue.

For many advanced medical technologies, the critical question is no longer simply:

“Can the device be sold?”

It is also:

“Can hospitals sustainably provide and charge for the clinical service enabled by the device?”

That distinction is particularly important for surgical robotics, AI-enabled devices, digital diagnostics and other technologies whose economic value is closely connected to clinical workflow.

Price Pressure Is Structural — Especially for High-Value Devices and Consumables

China’s healthcare system continues to place strong emphasis on affordability and healthcare-fund efficiency.

Centralized volume-based procurement has already reshaped multiple high-value medical consumable markets.

That pressure has not disappeared.

In its July 2026 briefing, the NHSA said it had launched a new round of national centralized procurement for high-value medical consumables and continued specific efforts to address excessive pricing.

For MedTech companies, however, “price pressure” should not be interpreted simply as a requirement to offer the lowest price.

The more important issue is economic value.

Hospitals increasingly evaluate:

• acquisition cost;

• disposable and consumable cost;

• maintenance and service expenses;

• utilization;

• staffing requirements;

• procedure economics;

• clinical differentiation;

• total cost over the equipment lifecycle.

This is particularly visible in capital-intensive categories such as surgical robotics.

In China’s orthopedic surgical robot procurement market, MedRobot found that publicly disclosed awarded volume increased by 29.4% year over year in H1 2026, while the estimated average procurement price fell from approximately RMB 8.90 million to RMB 6.98 million per system.

The market can therefore expand while individual equipment prices decline.

That pattern may become increasingly important across other capital-equipment categories.

The Commercial Model Is No Longer Limited to Selling a Machine

China’s hospital equipment market has traditionally been associated with capital purchases.

That is beginning to change.

In H1 2026, MedRobot identified six leasing projects in publicly disclosed orthopedic surgical robot procurement, involving TINAVI Medical and Longwood Valley MedTech. All six were awarded by leading tertiary hospitals in Beijing.

The sample is still limited, so it would be premature to describe leasing as the dominant model.

But its appearance is significant.

As hospitals become more cautious about capital expenditure, manufacturers are likely to experiment with different approaches to lowering the initial adoption barrier.

Depending on the device category, these may include:

• equipment leasing;

• managed-service arrangements;

• equipment-plus-consumables models;

• platform-based purchasing;

• regional shared-use models;

• staged deployment linked to utilization.

For international MedTech companies, the lesson is that a commercialization model successful in the United States or Europe may not map directly onto the economics of a Chinese hospital.

Product-market fit increasingly includes financial-model fit.

China Is Becoming Both a MedTech Market and a Global Supply Base

Perhaps the most important change is that China can no longer be analyzed purely as a destination market.

Chinese medical device companies are increasingly selling abroad.

Again, surgical robotics provides an unusually clear example.

Of at least 191 endoscopic surgical robot systems sold by Chinese manufacturers in H1 2026, MedRobot identified more than 154 overseas shipments from MicroPort MedBot, Sagebot and Cornerstone Robotics — approximately 81% of the category’s reported sales during the period.

This has several implications.

Chinese companies can use domestic R&D, engineering resources and supply chains while pursuing international regulatory approvals and overseas commercialization.

At the same time, multinational companies operating in China increasingly interact with Chinese suppliers and competitors that are themselves globalizing.

The traditional distinction between “the China market” and “the global market” is therefore becoming less useful in some advanced MedTech categories.

What Global MedTech Companies Should Watch

For international companies assessing China in 2026, five questions deserve particular attention:

The Bottom Line

China remains a large and strategically important MedTech market.

But “China is a large healthcare market” is no longer a sufficient market thesis.

The more useful framework in 2026 is to understand the complete path:

product → regulatory approval → hospital procurement → clinical use → service pricing → reimbursement → utilization → lifecycle economics.

Companies that understand only one part of that chain can easily misread the market.

MedChina will continue to track Chinese medical device companies, product approvals, hospital procurement, market data and policy developments to provide international MedTech professionals with a clearer view of how China’s medical technology market actually works.

August 18, 2026